Contemporary Practice and Considerations for Real‐World Data Source Identification and Feasibility Assessment
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5862 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Dony Patel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Global Database Studies Team, Real World Solutions IQVIA, London, UK. Hauptthemen laut MEDLINE: Pharmacoepidemiology, Feasibility Studies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ISPE, International Society for Pharmacoepidemiology.
Abstract (Originalsprache)
Purpose
There has been rapid growth in the variety and number of real‐world data (RWD) sources, as well as the number of regulatory documents that provide guidance for assessing the suitability of RWD sources for pharmacoepidemiology studies. This study aims to assess differences in RWD guidance and variability in current practice for identifying and assessing RWD for studies with regulatory purpose.
Methods
Key criteria for feasibility assessment were mapped against relevant regulatory guidance documents across US, EU, and Asia‐Pacific regions. An online survey was designed and deployed to International Society for Pharmacoepidemiology members to understand current practice. Findings were summarized and used to inform key considerations and recommendations.
Results
Eleven RWD guidance documents were identified and mapped against 14 RWD assessment criteria. Variability was seen across these documents in guidance for these criteria. Between December 2022 and January 2023, 37 survey respondents reported having used RWD for post‐marketing commitments (34, 92%) and/or background epidemiology (28, 76%). RWD were mostly identified through literature (33, 89%) and data landscaping (26, 70%); guidance documents referenced included: Food and Drug Administration (20, 54%), European Network for Centres for Pharmacoepidemiology and Pharmacovigilance (17, 46%), European Medical Agency (16, 43%), and Structured Process to Identify Fit‐For‐Purpose Data (11, 30%). Challenges for conducting feasibility assessments included RWD accessibility, ability to complete validation, and RWD provider responsiveness.
Conclusions
Existing guidelines are used extensively by researchers, but key criteria for RWD identification and feasibility assessment are not reflected consistently and challenges remain. Recommendations have been made reflecting study findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Global Database Studies Team, Real World Solutions IQVIA, London, UK.
- Epidemiology & Real World Science, Parexel International, Gothenberg, Sweden.
- Epidemiology, Global Regulatory Safety & Quality, GlaxoSmithKline, Philadelphia, USA.
- Global Database Studies Team, Real World Solutions, IQVIA, Espoo, Finland.
- Epidemiology, Biogen, Cambridge, USA.
- Global Database Studies Team, Real World Solutions, IQVIA, Tallin, Estonia.
ORCID-Profile: Dony Patel
Förderung
- ISPE
- International Society for Pharmacoepidemiology
Zitieren
APA
Patel, D., Guleria, S., Titievsky, L., Flaherty, S., Everage, N., Korjagina, M., Porkess, S., Kou, T. D., & Layton, D. (2024). Contemporary Practice and Considerations for Real‐World Data Source Identification and Feasibility Assessment. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5862
Vancouver
Patel D, Guleria S, Titievsky L, Flaherty S, Everage N, Korjagina M, et al. Contemporary Practice and Considerations for Real‐World Data Source Identification and Feasibility Assessment. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5862
BibTeX
@article{Patel2024,
author = {Patel, Dony and Guleria, Sonia and Titievsky, Lina and Flaherty, Susanna and Everage, Nicholas and Korjagina, Marta and Porkess, Sheuli and Kou, Tzuyung Douglas and Layton, Deborah},
title = {Contemporary Practice and Considerations for Real‐World Data Source Identification and Feasibility Assessment},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5862}
}
EUVIMED